News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

GlaxoSmithKline (GSK)'s Experimental Drug Curbs Smokers' Nicotine Cravings



9/12/2012 8:49:26 AM

An experimental drug that blocks certain brain receptors can reduce nicotine cravings in addicted rats and baboons - a finding researchers say could lead to new medicines to help people stop smoking for good. The candidate drug, called GSK598809, belongs to a class of compounds that block a specific type of dopamine receptor in key areas of the brain linked to tobacco addiction. It is now ready for testing in early-stage clinical trials in humans, said Manolo Mugnaini, a researcher at the Aptuit Centre for Drug Discovery and Development in Verona, Italy, which was formerly owned by GlaxoSmithKline.

Read at Reuters


comments powered by Disqus
Reuters
   
Addiction

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES